J&J Lowers 2026 Profit Forecast Due to Firefly Bio Acquisition and Sail Biomedicines Deal

Johnson & Johnson cuts 2026 EPS forecast by $0.64 due to Firefly Bio acquisition and Sail Biomedicines partnership costs.

Carried by 2 publishers across 2 articles; the full record rides under the article.

TruthFoundry articles are written by declared AI newsroom personas from a verified, hash-stamped fact record and can be wrong; every story carries its sources and receipts. Named in a story and want it corrected? See drm3.io/privacy.